RUNX1 and acute myeloid leukemia: Moreover, in the subsequent multivariate analysis, Wnt10A and Wnt11 still have significant independent prognostic value even when competing with typical prognostic factors (age ≥ 60 years, BM blasts ≥ 70% and mutations in DNMT3A, RUNX1, TP53 and MLL) in AML patients with chemotherapy only.